BridgeBio reports strong demand for Attruby post-FDA approval and enrollment completion in three Phase 3 trials, with significant financial backing. BridgeBio Pharma, Inc. announced significant ...
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a relatively recent addition to the 13F portfolio of Farallon Capital. The fund first ...
BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the stocks with explosive growth potential. On February 24, BridgeBio Pharma reported a transformative full-year 2025, marked by a surge in total revenue ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results